Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease

Neurobiology of Aging

Volumn 35, Issue 10, 2014, Pages 2302-2315

  Schlaudraff, Falk ^a   Gründemann, Jan ^b   Fauler, Michael ^a   Dragicevic, Elena ^a   Hardy, John ^c   Liss, Birgit ^a  

^a UNIVERSITY OF ULM   (Germany)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ATPase13A2; LRRK2; MiR 133b; Mixed effects model; NURR1; PARK; Parkin; PITX3; RIN; SNCA140; UCHL 1; UV LMD

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; MESSENGER RNA; MICRORNA; MICRORNA 133B; PARKIN; UNCLASSIFIED DRUG; MIRN133 MICRORNA, HUMAN; PROTEASOME;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; ATPASE13A2 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; GENE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PARK GENE; PARK5 GENE; PARK9 GENE; PARKINSON DISEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; TRANSCRIPTION REGULATION; UCHL1 GENE; VERY ELDERLY; AGING; COMPARATIVE STUDY; CYTOLOGY; DEFICIENCY; DIFFUSE LEWY BODY DISEASE; GENETICS; LYSOSOME; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY;

AGED; AGED, 80 AND OVER; AGING; ALPHA-SYNUCLEIN; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; HUMANS; LEWY BODY DISEASE; LYSOSOMES; MALE; MICRORNAS; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, MESSENGER; SUBSTANTIA NIGRA;

EID: 84903818720     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.03.016     Document Type: Article

References (91)

1. Ahn T.B., Langston J.W., Aachi V.R., Dickson D.W. Relationship of neighboring tissue and gliosis to α-synuclein pathology in a fetal transplant for Parkinson's disease. Am. J. Neurodegener. Dis. 2012, 1:49-59.
2. Auluck P.K., Caraveo G., Lindquist S. alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 2010, 26:211-233. 10.1146/annurev.cellbio.042308.113313.
3. Boger H.A., Mannangatti P., Samuvel D.J., Saylor A.J., Bender T.S., McGinty J.F., Fortress A.M., Zaman V., Huang P., Middaugh L.D., Randall P.K., Jayanthi L.D., Rohrer B., Helke K.L., Granholm A.C., Ramamoorthy S. Effects of brain-derived neurotrophic factor on dopaminergic function and motor behavior during aging. Genes Brain Behav. 2011, 10:186-198. 10.1111/j.1601-183X.2010.00654.x.
4. Bustin S.A., Beaulieu J.F., Huggett J., Jaggi R., Kibenge F.S., Olsvik P.A., Penning L.C., Toegel S. MIQE precis: practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments. BMC Mol. Biol. 2010, 11:74. 10.1186/1471-2199-11-74.
5. Caguci D.G. Sensitivity and Uncertainty Analysis - Volume 1: Theory 2003, Chapman&Hall/CRC Press, New York.
6. Consonni D., Bertazzi B.A., Zocchetti C. Why and how to control for age in occupational epidemiology. Occup. Environ. Med. 1997, 54:772-776. 10.1136/oem.54.11.772.
7. Członkowska A., Kurkowska-Jastrzebska I. Inflammation and gliosis in neurological diseases-clinical implications. J.Neuroimmunol. 2011, 231:78-85.
8. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122(Pt 8):1437-1448.
9. de Cremoux P., Valet F., Gentien D., Lehmann-Che J., Scott V., Tran-Perennou C., Barbaroux C., Servant N., Vacher S., Sigal-Zafrani B., Mathieu M.C., Bertheau P., Guinebretiere J.M., Asselain B., Marty M., Spyratos F. Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients. BMC Cancer 2011, 11:215. 10.1186/1471-2407-11-215.
10. de Mena L., Coto E., Cardo L.F., Diaz M., Blazquez M., Ribacoba R., Salvador C., Pastor P., Samaranch L., Moris G., Menendez M., Corao A.I., Alvarez V. Analysis of the Micro-RNA-133 and PITX3 genes in Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:1234-1239. 10.1002/ajmg.b.31086.
11. Devine M.J., Kaganovich A., Ryten M., Mamais A., Trabzuni D., Manzoni C., McGoldrick P., Chan D., Dillman A., Zerle J., Horan S., Taanman J.W., Hardy J., Marti-Masso J.F., Healey D., Schapira A.H., Wolozin B., Bandopadhyay R., Cookson M.R., van der Brug M.P., Lewis P.A. Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue. PLoS One 2011, 6:e22489.
12. Devine M.J., Ryten M., Vodicka P., Thomson A.J., Burdon T., Houlden H., Cavaleri F., Nagano M., Drummond N.J., Taanman J.W., Schapira A.H., Gwinn K., Hardy J., Lewis P.A., Kunath T. Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat. Commun. 2011, 2:440.
13. Elstner M., Morris C.M., Heim K., Bender A., Mehta D., Jaros E., Klopstock T., Meitinger T., Turnbull D.M., Prokisch H. Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropathol. 2011, 122:75-86. 10.1007/s00401-011-0828-9.
14. Eriksen J.L., Przedborski S., Petrucelli L. Gene dosage and pathogenesis of Parkinson's disease. Trends Mol. Med. 2005, 11:91-96. 10.1016/j.molmed.2005.01.001.
15. Fleige S., Pfaffl M.W. RNA integrity and the effect on the real-time qRT-PCR performance. Mol. Aspects Med. 2006, 27:126-139. 10.1016/j.mam.2005.12.003.
16. Fuchs J., Nilsson C., Kachergus J., Munz M., Larsson E.M., Schule B., Langston J.W., Middleton F.A., Ross O.A., Hulihan M., Gasser T., Farrer M.J. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007, 68:916-922. 10.1212/01.wnl.0000254458.17630.c5.
17. Fukuchi M., Fujii H., Takachi H., Ichinose H., Kuwana Y., Tabuchi A., Tsuda M. Activation of tyrosine hydroxylase (TH) gene transcription induced by brain-derived neurotrophic factor (BDNF) and its selective inhibition through Ca(2+) signals evoked via the N-methyl-D-aspartate (NMDA) receptor. Brain Res. 2010, 1366:18-26. 10.1016/j.brainres.2010.10.034.
18. Gasser T., Hardy J., Mizuno Y. Milestones in PD genetics. Mov. Disord. 2011, 26:1042-1048. 10.1002/mds.23637.
19. George S., Rey N.L., Reichenbach N., Steiner J.A., Brundin P. Alpha-synuclein: the long distance runner. Brain Pathol. 2013, 23:350-357. 10.1111/bpa.12046.
20. Gitler A.D., Chesi A., Geddie M.L., Strathearn K.E., Hamamichi S., Hill K.J., Caldwell K.A., Caldwell G.A., Cooper A.A., Rochet J.C., Lindquist S. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 2009, 41:308-315. 10.1038/ng.300.
21. Greene J.G. Current status and future directions of gene expression profiling in Parkinson's disease. Neurobiol. Dis. 2011, 45:76-82. 10.1016/j.nbd.2010.10.022.
22. Greenland S., Morgenstern H. Confounding in health research. Annu. Rev. Public Health 2001, 22:189-212.
23. Grundemann J., Schlaudraff F., Haeckel O., Liss B. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res. 2008, 36:e38. 10.1093/nar/gkn084.
24. Grundemann J., Schlaudraff F., Liss B. UV-laser microdissection and mRNA expression analysis of individual neurons from postmortem Parkinson's disease brains. Methods Mol. Biol. 2011, 755:363-374. 10.1007/978-1-61779-163-5_30.
25. Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron 2010, 68:201-206. 10.1016/j.neuron.2010.10.014.
26. Harraz M.M., Dawson T.M., Dawson V.L. MicroRNAs in Parkinson's disease. J.Chem. Neuroanat. 2011, 42:127-130. 10.1016/j.jchemneu.2011.01.005.
27. Harrison P.J., Heath P.R., Eastwood S.L., Burnet P.W., McDonald B., Pearson R.C. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci. Lett. 1995, 200:151-154.
28. Heyer M.P., Pani A.K., Smeyne R.J., Kenny P.J., Feng G. Normal midbrain dopaminergic neuron development and function in miR-133b mutant mice. J.Neurosci. 2012, 32:10887-10894. 10.1523/JNEUROSCI.1732-12.2012.
29. Hindle J.V. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010, 39:156-161. 10.1093/ageing/afp223.
30. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397. 10.1016/S1474-4422(09)70062-6.
31. Ho-Pun-Cheung A. Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization. BMC Mol. Biol. 2009, 10:31.
32. Jowaed A., Schmitt I., Kaut O., Wullner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J.Neurosci. 2010, 30:6355-6359. 10.1523/JNEUROSCI.6119-09.2010.
33. Jung M., Schaefer A., Steiner I., Kempkensteffen C., Stephan C., Erbersdobler A., Jung K. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin. Chem. 2010, 56:998-1006. 10.1373/clinchem.2009.141580.
34. Junn E., Mouradian M.M. MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol. Ther. 2012, 133:142-150. 10.1016/j.pharmthera.2011.10.002.
35. Kalia L.V., Kalia S.K., McLean P.J., Lozano A.M., Lang A.E. -Synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol. 2013, 73:155-169. 10.1002/ana.23746.
36. Kalivendi S.V., Yedlapudi D., Hillard C.J., Kalyanaraman B. Oxidants inducealternative splicing of alpha-synuclein: implications for Parkinson's disease. Free Radic. Biol. Med. 2009, 48:377-383. 10.1016/j.freeradbiomed.2009.10.045.
37. Kamp F., Exner N., Lutz A.K., Wender N., Hegermann J., Brunner B., Nuscher B., Bartels T., Giese A., Beyer K., Eimer S., Winklhofer K.F., Haass C. Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 2010, 29:3571-3589. 10.1038/emboj.2010.223.
38. Kim J., Inoue K., Ishii J., Vanti W.B., Voronov S.V., Murchison E., Hannon G., Abeliovich A. AMicroRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317:1220-1224. 10.1126/science.1140481.
39. Koppelkamm A., Vennemann B., Lutz-Bonengel S., Fracasso T., Vennemann M. RNA integrity in post-mortem samples: influencing parameters and implications on RT-qPCR assays. Int. J. Legal Med. 2011, 125:573-580.
40. Lesnick T.G., Papapetropoulos S., Mash D.C., Ffrench-Mullen J., Shehadeh L., deAndrade M., Henley J.R., Rocca W.A., Ahlskog J.E., Maraganore D.M. Agenomic pathway approach to a complex disease: axon guidance andParkinson disease. PLoS Genet. 2007, 3:e98. 10.1371/journal.pgen.0030098.
41. Li X., Patel J.C., Wang J., Avshalumov M.V., Nicholson C., Buxbaum J.D., Elder G.A., Rice M.E., Yue Z. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J.Neurosci. 2010, 30:1788-1797. 10.1523/JNEUROSCI.5604-09.2010.
42. Lin X., Parisiadou L., Gu X.L., Wang L., Shim H., Sun L., Xie C., Long C.X., Yang W.J., Ding J., Chen Z.Z., Gallant P.E., Tao-Cheng J.H., Rudow G., Troncoso J.C., Liu Z., Li Z., Cai H. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827. 10.1016/j.neuron.2009.11.006.
43. Lombardino A.J., Li X.C., Hertel M., Nottebohm F. Replaceable neurons and neurodegenerative disease share depressed UCHL1 levels. Proc. Natl. Acad. Sci. U.S.A 2005, 102:8036-8041. 10.1073/pnas.0503239102.
44. Lundblad M., Decressac M., Mattsson B., Bjorklund A. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. U.S.A 2012, 109:3213-3219.
45. Mandel S., Grunblatt E., Riederer P., Amariglio N., Jacob-Hirsch J., Rechavi G., Youdim M.B. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann. N. Y. Acad. Sci. 2005, 1053:356-375. 10.1196/annals.1344.031.
46. McCarthy J.J., Linnertz C., Saucier L., Burke J.R., Hulette C.M., Welsh-Bohmer K.A., Chiba-Falek O. The effect of SNCA 3' region on the levels of SNCA-112 splicing variant. Neurogenetics 2011, 12:59-64. 10.1007/s10048-010-0263-4.
47. McLean J.R., Hallett P.J., Cooper O., Stanley M., Isacson O. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol. Cell Neurosci. 2011, 49:230-239. 10.1016/j.mcn.2011.11.006.
48. McNamee R. Regression modelling and other methods to control confounding. Occup. Environ. Med. 2005, 62:500-506.
49. Meissner W.G., Frasier M., Gasser T., Goetz C.G., Lozano A., Piccini P., Obeso J.A., Rascol O., Schapira A., Voon V., Weiner D.M., Tison F., Bezard E. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 2011, 10:377-393. 10.1038/nrd3430.
50. Mexal S., Berger R., Adams C.E., Ross R.G., Freedman R., Leonard S. Brain pH has a significant impact on human postmortem hippocampal gene expression profiles. Brain Res. 2006, 1106:1-11. 10.1016/j.brainres.2006.05.043.
51. Minones-Moyano E., Porta S., Escaramis G., Rabionet R., Iraola S., Kagerbauer B., Espinosa-Parrilla Y., Ferrer I., Estivill X., Marti E. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum. Mol. Genet. 2011, 20:3067-3078. 10.1093/hmg/ddr210.
52. Mittag F., Buchel F., Saad M., Jahn A., Schulte C., Bochdanovits Z., Simon-Sanchez J., Nalls M.A., Keller M., Hernandez D.G., Gibbs J.R., Lesage S., Brice A., Heutink P., Martinez M., Wood N.W., Hardy J., Singleton A.B., Zell A., Gasser T., Sharma M. Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunities. Hum. Mutat. 2012, 33:1708-1718. International Parkinson's Disease Genomics Consortium. 10.1002/humu.22161.
53. Moran L.B., Duke D.C., Deprez M., Dexter D.T., Pearce R.K., Graeber M.B. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 2006, 7:1-11. 10.1007/s10048-005-0020-2.
54. Moran L.B., Graeber M.B. Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics 2008, 9:1-13. 10.1007/s10048-007-0116-y.
55. Moszczynska A., Saleh J., Zhang H., Vukusic B., Lee F.J., Liu F. Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity. J.Mol. Neurosci. 2007, 32:217-227.
56. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M., Simon-Sanchez J., Schulte C., Lesage S., Sveinbjornsdottir S., Stefansson K., Martinez M., Hardy J., Heutink P., Brice A., Gasser T., Singleton A.B., Wood N.W. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649. 10.1016/S0140-6736(10)62345-8.
57. Opitz L., Salinas-Riester G., Grade M., Jung K., Jo P., Emons G., Ghadimi B.M., Beissbarth T., Gaedcke J. Impact of RNA degradation on gene expression profiling. BMC Med. Genomics 2010, 3:36. 10.1186/1755-8794-3-36.
58. Palm T., Bahnassawy L., Schwamborn J. MiRNAs and neural stem cells: a team to treat Parkinson's disease?. RNA Biol. 2012, 9:720-730. 10.4161/rna.19984.
59. Pihlstrom L., Toft M. Genetic variability in SNCA and Parkinson's disease. Neurogenetics 2011, 12:283-293. 10.1007/s10048-011-0292-7.
60. Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D., Team, t.R.D.C. 2012. nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-104.
61. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
62. Popova T., Mennerich D., Weith A., Quast K. Effect of RNA quality on transcript intensity levels in microarray analysis of human post-mortem brain tissues. BMC Genomics 2008, 9:91. 10.1186/1471-2164-9-91.
63. Prasad K., Tarasewicz E., Strickland P.A., O'Neill M., Mitchell S.N., Merchant K., Tep S., Hilton K., Datwani A., Buttini M., Mueller-Steiner S., Richfield E.K. Biochemical and morphological consequences of human alpha-synuclein expression in a mouse alpha-synuclein null background. Eur. J. Neurosci. 2011, 33:642-656. 10.1111/j.1460-9568.2010.07558.x.
64. Radi E., Formichi P., Di Maio G., Battisti C., Federico A. Altered apoptosis regulation in kufor-rakeb syndrome patients with mutations in the ATP13A2 gene. J.Cell Mol. Med. 2011, 16:1916-1923. 10.1111/j.1582-4934.2011.01488.x.
65. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., Goebel I., Mubaidin A.F., Wriekat A.L., Roeper J., Al-Din A., Hillmer A.M., Karsak M., Liss B., Woods C.G., Behrens M.I., Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 2006, 38:1184-1191. 10.1038/ng1884.
66. Ransdell J.L., Faust T.B., Schulz D.J. Correlated levels of mRNA and soma size in single identified neurons: evidence for compartment-specific regulation of gene expression. Front. Mol. Neurosci. 2010, 3:116. 10.3389/fnmol.2010.00116.
67. Reddy S.D., Rayala S.K., Ohshiro K., Pakala S.B., Kobori N., Dash P., Yun S., Qin J., O'Malley B.W., Kumar R. Multiple coregulatory control of tyrosine hydroxylase gene transcription. Proc. Natl. Acad. Sci. U.S.A 2011, 108:4200-4205. 10.1073/pnas.1101193108.
68. Salmena L., Poliseno L., Tay Y., Kats L., Pandolfi P.P. AceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell 2011, 146:353-358. 10.1016/j.cell.2011.07.014.
69. Scherzer C.R., Jensen R.V., Gullans S.R., Feany M.B. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. Hum. Mol. Genet. 2003, 12:2457-2466. 10.1093/hmg/ddg265.
70. Schulz D.J., Goaillard J.M., Marder E.E. Quantitative expression profiling of identified neurons reveals cell-specific constraints on highly variable levels of gene expression. Proc. Natl. Acad. Sci. U.S.A 2007, 104:13187-13191. 10.1073/pnas.0705827104.
71. Schwarz G. Estimating the dimension of a Model. Ann. Statist. 1978, 6:461-464.
72. Shulman J.M., De Jager P.L., Feany M.B. Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol. 2011, 6:193-222. 10.1146/annurev-pathol-011110-130242.
73. Simunovic F., Yi M., Wang Y., Macey L., Brown L.T., Krichevsky A.M., Andersen S.L., Stephens R.M., Benes F.M., Sonntag K.C. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 2009, 132(Pt 7):1795-1809. 10.1093/brain/awn323.
74. Snijders T.A., Bosker R. Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling 2011, Sage, London. second ed.
75. Sonntag K.C. MicroRNAs and deregulated gene expression networks in neurodegeneration. Brain Res. 2010, 1338:48-57. 10.1016/j.brainres.2010.03.106.
76. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840. 10.1038/42166.
77. Stahlberg A., Andersson D., Aurelius J., Faiz M., Pekna M., Kubista M., Pekny M. Defining cell populations with single-cell gene expression profiling: correlations and identification of astrocyte subpopulations. Nucleic Acids Res. 2011, 39:e24. 10.1093/nar/gkq1182.
78. Tang F., Lao K., Surani M.A. Development and applications of single-cell transcriptome analysis. Nat. Methods 2011, 8(4 Suppl):S6-S11. 10.1038/nmeth.1557.
79. Tobin A.E., Cruz-Bermudez N.D., Marder E., Schulz D.J. Correlations in ion channel mRNA in rhythmically active neurons. PLoS One 2009, 4:e6742. 10.1371/journal.pone.0006742.
80. Ugolino J., Fang S., Kubisch C., Monteiro M.J. Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death. Hum. Mol. Genet. 2011, 20:3565-3577. 10.1093/hmg/ddr274.
81. Vartiainen S., Pehkonen P., Lakso M., Nass R., Wong G. Identification ofgeneexpression changes in transgenic C. elegans overexpressing human alpha-synuclein. Neurobiol. Dis. 2006, 22:477-486. 10.1016/j.nbd.2005.12.021.
82. Venda L.L., Cragg S.J., Buchman V.L., Wade-Martins R. -Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 2010, 33:559-568. 10.1016/j.tins.2010.09.004.
83. Vermeulen J., De Preter K., Lefever S., Nuytens J., De Vloed F., Derveaux S., Hellemans J., Speleman F., Vandesompele J. Measurable impact of RNA quality on gene expression results from quantitative PCR. Nucleic Acids Res. 2011, 39:e63. 10.1093/nar/gkr065.
84. Volpicelli F., De Gregorio R., Pulcrano S., Perrone-Capano C., di Porzio U., Bellenchi G.C. Direct regulation of Pitx3 expression by Nurr1 in culture and in developing mouse midbrain. PLoS One 2012, 7:e30661. 10.1371/journal.pone.0030661.
85. Wang G., van der Walt J.M., Mayhew G., Li Y.J., Zuchner S., Scott W.K., Martin E.R., Vance J.M. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am. J. Hum. Genet. 2008, 82:283-289. 10.1016/j.ajhg.2007.09.021.
86. Yasuda T., Nihira T., Ren Y.R., Cao X.Q., Wada K., Setsuie R., Kabuta T., Hattori N., Mizuno Y., Mochizuki H. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease. J.Neurochem. 2009, 108:932-944. 10.1111/j.1471-4159.2008.05827.x.
87. Yeger-Lotem E., Riva L., Su L.J., Gitler A.D., Cashikar A.G., King O.D., Auluck P.K., Geddie M.L., Valastyan J.S., Karger D.R., Lindquist S., Fraenkel E. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat. Genet. 2009, 41:316-323. 10.1038/ng.337.
88. Youle R.J., Narendra D.P. Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 2011, 12:9-14.
89. Zhang Y., James M., Middleton F.A., Davis R.L. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 137B:5-16. 10.1002/ajmg.b.30195.
90. Zhou Z., Kim J., Insolera R., Peng X., Fink D.J., Mata M. Rho GTPase regulation of alpha-synuclein and VMAT2: implications for pathogenesis of Parkinson's disease. Mol. Cell Neurosci. 2011, 48:29-37. 10.1016/j.mcn.2011.06.002.
91. Ziebell M., Khalid U., Klein A.B., Aznar S., Thomsen G., Jensen P., Knudsen G.M. Striatal dopamine transporter binding correlates with serum BDNF levelsin patients with striatal dopaminergic neurodegeneration. Neurobiol. Aging 2010, 33:428.e1-428.e5. 10.1016/j.neurobiolaging.2010.11.010.